Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of an early therapeutic permutation on the tumoral control of patients receiving in first line a specific inhibitor of tyrosin kinase of EGFR [epidermal growth factor receptor] (erlotinib) or a taxan-based chemotherapy [paclitaxel] for the treatment of not resectable adenocarcinoma with bronchiolo-alveolar [bronchiolo-alveolar adenocarcinoma].

Trial Profile

Effect of an early therapeutic permutation on the tumoral control of patients receiving in first line a specific inhibitor of tyrosin kinase of EGFR [epidermal growth factor receptor] (erlotinib) or a taxan-based chemotherapy [paclitaxel] for the treatment of not resectable adenocarcinoma with bronchiolo-alveolar [bronchiolo-alveolar adenocarcinoma].

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2015

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
  • Indications Bronchiolo-alveolar adenocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2015 Primary endpoint (16-week Disease Control Rate) has been met according to the results published in the European Respiratory Journal.
    • 17 Sep 2015 Results published in the European Respiratory Journal.
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top